Learn

This is a summary of a dinner meeting discussing the evolving landscapes in ovarian cancer and endometrial cancer, and focussing on two new PBS listings for niraparib and dostarlimab. The speakers included Dr Michelle Harrison as Chair, Associate Professor Rhonda Farrell, Dr Sally Baron Hay and Dr Vivek Rathi.

In August 2024, GSK hosted a series of educational dinner meetings to discuss the evolving landscapes in ovarian cancer (OC) and endometrial cancer (EC), and to focus on two new Pharmaceutical Benefits Scheme (PBS) listings:

• Niraparib for maintenance treatment of homologous recombination deficient (HRd) BRCAmut and HRd BRCAwt advanced OC following a response [e.g., complete response (CR) or partial response (PR)] to first-line platinum-based chemotherapy.

• Dostarlimab in combination with platinum-containing chemotherapy as a first-line treatment for women with deficient mismatch repair (dMMR) primary advanced or recurrent EC.

In NSW, attendees heard from nationally renowned speakers, who shared key updates and insights. This newsletter highlights the main themes from these informative presentations.

Details

A summary of a recent presentation titled: Time to Bloom: Expanding the World of Gynaecologic Oncology.

This activity is accepted by CPD Home as a Domain 1: Educational Activity - Professional Reading in alignment with the CPD Home Program Guide. 

Disclaimer: Please note, once you click 'Enrol now' you will be leaving the AMA’s CPD Home website and entering a third-party website.